Amryt Pharma Holdings Ltd
LSE:AMYT
Amryt Pharma Holdings Ltd
Interest Income Expense
Amryt Pharma Holdings Ltd
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
Interest Income Expense
-$19.6m
|
CAGR 3-Years
-175%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Interest Income Expense
-£641m
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
AstraZeneca PLC
LSE:AZN
|
Interest Income Expense
-$1.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
Indivior PLC
LSE:INDV
|
Interest Income Expense
$9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Interest Income Expense
-$67m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Interest Income Expense
-£21m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-14%
|
See Also
What is Amryt Pharma Holdings Ltd's Interest Income Expense?
Interest Income Expense
-19.6m
USD
Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Interest Income Expense amounts to -19.6m USD.
What is Amryt Pharma Holdings Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-175%
Over the last year, the Interest Income Expense growth was -311%. The average annual Interest Income Expense growth rates for Amryt Pharma Holdings Ltd have been -175% over the past three years .